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Dear Editor,  
 
We agree with S Ellenberg and colleagues’ assertion that an important 
opportunity was lost during the 2013-2016 West African Ebola virus outbreak 
in the evaluation of potentially life-saving treatments for Ebola virus disease 
(EVD) (1). Among the five therapeutic trials conducted, none of them evaluated 
the efficacy of an optimised supportive treatment (OST) backbone. Though one 
RCT aimed to evaluate the efficacy of ZMapp and OST compared to OST 
alone, the trial results are difficult to interpret given the paucity of data 
describing the comparability of OST delivery across study arms (2). 
Importantly, the improved survival (18.5%) among persons with EVD treated in 
the United States and Europe is less attributable to experimental treatment (less 
than 50% of patients received a completed course of an experimental 
therapeutic) and more attributable to OST, namely close monitoring and 
aggressive supportive care including intravenous fluid hydration, correction of 
electrolyte abnormalities, nutritional support, and critical care management for 
respiratory and renal failure (6). We acknowledge that many challenges to 
delivering OST exist in settings such as those most affected by the West Africa 
outbreak including treatment centres overwhelmed by patients, lack of adequate 
health care infrastructure, lack of trained health care workers, and duration of 
time to deliver care constrained by personal protective equipment (3). These 
challenges, however, should not impede including the provision and evaluation 
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of OST in a well-resourced clinical trial. While others have previously stated 
that “conventional care offers little benefit” despite lack of evidence to support 
this claim (5), better attempts to incorporate evaluation of OST in a clinical trial 
might have provided pragmatic evidence (e.g., on fluid resuscitation and 
monitoring) to help guide frontline clinicians on how best to manage EVD 
patients in light of resource constraints.  
Ultimately, while “consensus about trial design and conduct in inter-epidemic 
periods” is important, strengthening the local infrastructure and training local 
health care workers to deliver evidence-based OST should also be prioritised. 
This approach is important not only to address future filovirus outbreaks but 
also to prepare for other epidemics with highly infectious and deadly 
pathogens.  
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